|Bid||61.34 x 900|
|Ask||71.84 x 3100|
|Day's Range||62.61 - 66.07|
|52 Week Range||37.36 - 81.22|
|Beta (3Y Monthly)||0.87|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||86.09|
MADISON, Wis. and SAN DIEGO, Oct. 18, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced the acquisition of Biomatrica, a leading developer, manufacturer and provider of sample preservation technology, including blood and saliva sample collection tubes, to the biotech industry. Biomatrica's sample collection tubes, which contain proprietary, sample-stabilizing chemistry, ensure quality preservation of circulating tumor DNA, cells and other biomarkers in biological specimens throughout shipment and storage. Exact Sciences intends to use Biomatrica's proprietary technology to support ongoing and future development of its own blood-based cancer detection tests.
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Exact Sciences Corporation (NASDAQ:EXAS), with a market capitalization of US$8.3b, rarely draw their attention from the investing Read More...
MADISON, Wis., Oct. 8, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that the company plans to release its third-quarter 2018 financial results after the close of the U.S. financial markets on Oct. 30, 2018. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
NEW YORK, Oct. 04, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Today, TG Therapeutics stock is trading at a price of $5.82, which is ~37.0% down from yesterday’s closing price of $9.25. The stock also hit a 52-week low of $5.70. TG Therapeutics had hit a 52-week high of $17.35 on March 9. Reason for the decline
Exact Sciences (EXAS) stock has reported a 67.1% rise in the last month, from $49.93 on August 10 to $75.99 on September 10. Its performance was mainly due to its collaboration with Pfizer (PFE) for the increasing adoption of Exact Sciences’ Cologuard non-invasive stool DNA test for colorectal cancer screening in the United States. According to the collaboration announced on August 22, Pfizer will actively participate in promoting Cologuard until 2021.
MADISON, Wis., Aug. 31, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conferences during September and invited investors to participate by webcast. The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer.
NEW YORK, NY / ACCESSWIRE / August 24, 2018 / U.S. markets plunged on Thursday following the release of the minutes from the latest Federal Reserve meeting, which called for an interest hike in September. ...
Exact Sciences (NASDAQ:EXAS) shares have bolted above both their 50-day and 200-day moving averages, rising nearly 30% in mid-day trading on Wednesday to return to the upper end of a three-month trading range. The company will next report results on Oct. 31, after the bell. When the company last reported on Aug. 1, a loss of 30-cents-per-share beat estimates by 3 cents on a 79% rise in revenues on a year-over-year basis.
Exact Sciences (EXAS) reaches a co-promotion agreement with Pfizer to commercialize its non-invasive screening test for colorectal cancer, Cologuard. The stock rallies following this news.
NEW YORK, NY / ACCESSWIRE / August 23, 2018 / Exact Sciences made headlines on Wednesday, announcing an agreement with Pfizer to share marketing expenses and to co-promote the company’s Colorguard colorectal ...
Stocks that moved substantially or traded heavily Wednesday: Target Corp., up $2.67 to $85.94 The retailer raised its annual forecasts as its sales over the internet and in stores both climbed. Lowe's ...
Exact Sciences doesn’t do glamorous work, but on Wednesday its shareholders got beautiful results. The health-care company announced a collaboration deal with Pfizer to market its signature product, Cologuard, a stool DNA screening test for colorectal cancer.
On August 22, Exact Sciences (EXAS) is trading at a stock price of $62.95, which represents ~25.78% growth from the close of $50.05 on August 21.
Jim Cramer chats with Exact Sciences' CEO Kevin Conroy about the company's new partnership with Pfizer and its long-term goals.